Topas Therapeutics GmbH’s Post

Why visit booth 📍1411 at The Liver Meeting 2024? 👀 See hepatoSIGHT™ for yourself. 🏥 Hear how we're helping end the late diagnosis of liver disease: Learn how our technology helps clinicians efficiently identify patients at risk of liver disease, pinpointing cases earlier than ever. This approach enables a proactive approach to disease management, ensuring care is provided in the optimal setting. 💊 Learn how we can accelerate clinical trials: Discover how hepatoSIGHT™ can make participant recruitment for your trials streamlined by identifying high-risk populations quickly and accurately. This speeds up recruitment trial timelines and improves the precision of patient selection. 💡 Read our latest research: We're showcasing three posters from our collaborators, each offering new insights and findings using hepatoSIGHT™. Read more here: https://lnkd.in/eWjRFPtP? 🤝 Meet the expert team who developed hepatoSIGHT™: Connect with the Predictive Health Intelligence team and learn more about how we developed hepatoSIGHT and our recent milestones for the product. 📍 Come and visit us in San Diego, booth 1411. #LiverResearch #TheLiverMeeting #hepatoSIGHT | Tim Jobson | Neil Stevens CHCIO | Mark Wall | James H.

We (Marko Lucijanic, Anica Sabljic, Ivan Krečak) had the privilege of contributing the Letter to the Editor to the New England Journal of Medicine (#NEJM) in which we comment on the safety aspects of #belantamabmafodotin, a potent novel treatment for patients with relapsed #multiplemyeloma. As multiple #myeloma remains a challenging disease, we are very honored to engage in this important discussion. NEJM Group #cancerresearch #immunotherapy https://lnkd.in/evYe8FzN https://lnkd.in/evTwke_n

🚨 Big news from Vesalio! 🚨 We’re launching a U.S. clinical study for our pVasc™ Thrombectomy System, designed to address the challenges of removing thromboemboli in acute limb ischemia (#ALI). The #pVasc Study will gather real-world data to help optimize revascularization strategies in supporting patients with peripheral arterial disease (#PAD). We’re looking forward to connecting with industry experts at the upcoming TCT, VIVA, and VEITH conferences to share insights on our advancements and discuss the future of vascular health. Read Press Release: https://lnkd.in/g9ysv9Wd This is just the beginning—stay tuned for more updates as we continue pushing the boundaries of endovascular innovation! 💡 #DoTheDropZone #PeripheralThrombectomy #AcuteLimbIschemia #PeripheralArterialDisease

We're thrilled to launch our groundbreaking Set of Patient-Centered Outcome Measures for Adults living with Obesity, a complex, chronic, relapsing disease with a wide array of consequences, including increased risk of stroke, heart disease, and certain types of cancer. This new set prioritizes what truly matters to patients: their physical, social, and emotional well-being. This landmark achievement in value-based healthcare redefines patient care by focusing on outcomes that impact daily life. Developed with input from patients, top physicians, and measurement experts, it's a global game-changer. Recognized worldwide, these measures are implemented in 42 countries, addressing 60% of the global disease burden. A huge thank you to our amazing sponsors: Novo Nordisk, Eli Lilly and Company, and Boehringer Ingelheim. Find out more and download the Obesity Set here: https://bit.ly/4cK6dJd #HealthcareInnovation #PatientCare #ObesityAwareness #ICHOM #ValueBasedCare

Making a difference by focusing all stakeholders on the outcomes that matter to people living with obesity. Proud of International Consortium for Health Outcomes Measurement (ICHOM) and the international team that did this work. Now, let’s use these measures to improve care and inform better decision making at all levels. #measurewhatmatters #patientcentered #healthoutcomes

With the final day of Medlab Middle East 2024 upon us, join us during our medlab sessions as our healthcare professionals talk on important topics such as quality goals and biomarkers for alzheimers disease. #NRL #healthcare #science

Our Mitochondrial and inhertited metabolic disease taskforce led by Critical Path Institute (C-Path) now has a mission statement accepted by the members! Our mission is: ☑ Standardizing and integrating mitochondrial and inherited metabolic diseases data into the RDCA-DAP®. ☑ Optimizing clinical trial design and endpoints. ☑ Enhancing communication and collaboration among stakeholders, and the medical and research communities at large, all aimed at improving the lives of those affected by these diseases. #mitochondrialdisease #leighsyndrome

📣 NEW! LightCure Consortium receives Horizon Europe Grant. 💡 Congenital Hyperinsulinism International (CHI) is excited to announce we are part of a new 11-member research consortium called LightCure. The LightCure Consortium is developing a targeted photodynamic therapy, that one day could be a promising treatment for congenital hyperinsulinism (HI). 💙 This project is made possible by a 72-month-long grant of just over €8.2M from the European Union research arm Horizon Europe and encompasses CHI’s work to strengthen patient engagement and raise worldwide awareness of HI and its myriad challenges. 🔗 You can find more information about this exciting project at https://lnkd.in/eVq-2Faa #hyperinsulinism #raredisease #congenitalhyperinsulinism #hypoglycemia | Hyperinsulinism | Congenital | HI | Hypoglycemia | Rare Disease

We talk so often about costs in healthcare, but how often do we pause to ask: Whose costs? I'm looking forward to this The Innovation and Value Initiative (IVI) webinar to explore the full range of economic impacts that patients and their families experience. #healthequity #measurewhatmatters #livedexperience

In a new article in collaboration with Technology Networks Hsuan (Tina) Chou, PhD and Lucy Godbeer of Owlstone Medical explore how breath analysis could enable more comfortable and non-invasive sampling for cystic fibrosis patients. Click the link to find out more about the complexities of cystic fibrosis, the need for disease monitoring, and the potential of breath analysis to improve long-term management. https://ow.ly/VL2c50RGOzw #cysticfibrosis #diseasemanagement #breath #non-invasive